• 1.哈爾濱醫(yī)科大學(xué)附屬第二醫(yī)院心血管外科心肌缺血機(jī)理與診療技術(shù)省部共建教育部重點(diǎn)實(shí)驗(yàn)室， 哈爾濱 150086;;
  • 2.哈爾濱醫(yī)科大學(xué)附屬第二醫(yī)院兒內(nèi)科，哈爾濱 150086;;
  • 3.雞西市人民醫(yī)院胸心血管外科， 黑龍江雞西 158100;

目的 　探討建立大鼠室壁瘤左心室重建（ LVR）動(dòng)物模型的可行性。方法 　對35只成年雄性 Sprague-Dawley（SD）大鼠實(shí)施左冠狀動(dòng)脈前降支結(jié)扎以制作心肌梗死后室壁瘤（ LVA）模型， 4周后，對符合入選標(biāo)準(zhǔn)的 16只 LVA模型實(shí)施 LVR手術(shù)，作為實(shí)驗(yàn)組；另 10只模型行開胸手術(shù)作為對照組，在術(shù)后 3 d、2周、4周分別以超聲心動(dòng)圖評價(jià)兩組大鼠心功能情況，以直視攝片、 Masson’s Trichrome 染色評價(jià)室壁瘤切除的徹底程度。結(jié)果 　LVA模型及 LVR模型的死亡率分別為 11.4%（4/35） 及 18.8%（3/16），建模成功率分別為 74.3%（26/35）和 81.3%（13/16）。直視攝片及 Masson’s Trichrome 染色提示補(bǔ)片完全替代心肌梗死瘢痕。超聲心動(dòng)圖提示：行 LVR手術(shù)的實(shí)驗(yàn)組動(dòng)物的左心室收縮期末內(nèi)徑（ LVESD）及左心室短軸縮短率（ FS）在術(shù)后 3 d即較對照組有所改善［術(shù)后 3 d：LVESD （5.00±0.87）mm vs.（5.90±0.92）mm, P＜0.05；FS（34.20%±6.80%）vs.（26.60%±6.12%）, P＜0.01］，隨著時(shí)間的推移，施行 LVR手術(shù)的實(shí)驗(yàn)組大鼠比對照組更好地維持了左心形態(tài)及收縮功能［術(shù)后 2周：左心室舒張期末內(nèi)徑（LVEDD）（7.60±0.56）mm vs.（8.50±1.08）mm，P＜0.01；LVESD（5.10±0.65） mm vs.（6.69±0.89）mm，P＜ 0.001；FS（31.90%±6.90%）vs.（21.10%±6.17%），P＜0.001；術(shù)后 4周：LVEDD（7.70±0.50）mm vs.（9.10± 0.89） mm，P＜ 0.001；LVESD（5.20±0.39）mm vs.（7.20±0.95）mm，P＜ 0.001；FS（31.80%±2.40%）vs.（20.20%±4.17%），P＜0.001］。結(jié)論 　大鼠 LVR模型可作為組織工程心肌補(bǔ)片（ EHT）研究中一種穩(wěn)定、可靠、經(jīng)濟(jì)的初選模型。

引用本文： 康凱,曲輝,湯繼權(quán)等. 大鼠室壁瘤左心室重建模型的建立. 中國胸心血管外科臨床雜志, 2012, 19(3): 293-297. doi: 復(fù)制

版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《中國胸心血管外科臨床雜志》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編

1. 　Di Donato M, Sabatier M, Dor V, et a1. Effects of the Dor procedure on left ventricular dimension and shape and geometric correlates of mitral regurgitation one year after surgery. J Thorac Cardiovasc Surg, 2001, 121 （1）：91-96.
2. 　Horii T, Tambara K, Nishimura K, et a1. Residual fibrosis affects a long-term result of left ventricular volume reduction surgery for dilated cardiomyopathy in a rat experimental study. Eur J Cardiothorac Surg, 2004, 26 （6）：1174-1179.
3. 　Zhang C, Hou J, Zheng S, et a1. Vascularized atrial tissue patch cardiomyoplasty with omentopexy improves cardiac performance after myocardial infarction. Ann Thorac Surg, 2011, 92 （4）：1435-1442.
4. 　Yuan Ye K, Sullivan KE, Black LD. Encapsulation of cardiomyocytes in a fibrin hydrogel for cardiac tissue engineering. J Vis Exp, 2011, （55）：3251.
5. 　Wang B, Borazjani A, Tahai M, et a1. Fabrication of cardiac patch with decellularized porcine myocardial scaffold and bone marrow mononuclear cells. J Biomed Mater Res A, 2010, 94 （4）：1100-1110.
6. 　Chiu LY, Radisic M. Scaffolds with covalently immobilized VEGF and Angiopoietin-1 for vascularization of engineered tissues. Biomaterials, 2010, 31 （2）：226-241.
7. 　Cui J, Li J, Mathison M, et a1. A clinically relevant large-animal model for evaluation of tissue-engineered cardiac surgical patch materials. Cardiovasc Revasc Med, 2005, 6 （3）：113-120.
8. 　Ratcliffe MB, Wallace AW, Salahieh A, et a1. Ventricular volume, chamber stiffness, and function after anteroapical aneurysm plication in the sheep. J Thorac Cardiovasc Surg, 2000, 119 （1）：115-124.
9. 　Pozzobon M, Bollini S, Iop L, et a1. Human bone marrow-derived CD133 （＋） cells delivered to a collagen patch on cryoinjured rat heart promote angiogenesis and arteriogenesis. Cell Transplant, 2010, 19 （10）：1247-1260.
10. 　Gaebel R, Ma N, Liu J, et a1. Patterning human stem cells and endothelial cells with laser printing for cardiac regeneration. Biomaterials, 2011, 32 （35）：9218-9230.
11. 　Yoshikawa E, Marui A, Tsukashita M, et a1. Carvedilol may alleviate late cardiac remodelling following surgical ventricular restoration. Eur J Cardiothorac Surg, 2010, 37 （2）：362-367.
12. 　Hsu CP, Huang CY, Wang JS, et a1. Extracellular matrix remodeling attenuated after experimental postinfarct left ventricular aneurysm repair. Ann Thorac Surg, 2008, 86 （4）：1243-1249.
13. 　Matsubayashi K, Fedak PW, Mickle DA, et a1. Improved left ventricular aneurysm repair with bioengineered vascular smooth muscle grafts. Circulation, 2003, 108 （Suppl 1）：II219-II225.
14. 　Di Donato M, Castelvecchio S, Menicanti L. Surgical treatment of ischemic heart failure：the Dor procedure. Circ J, 2009, 73 （Suppl A）：A1-A5.
15. 　Sakamoto Y, Mizuno A, Buckberg GD, et a1. Restoring the remodeled enlarged left ventricle：experimental benefits of in vivo porcine cardioreduction in the beating open heart. J Card Surg, 1998, 13 （6）：429-439.
  1. 1. 　Di Donato M, Sabatier M, Dor V, et a1. Effects of the Dor procedure on left ventricular dimension and shape and geometric correlates of mitral regurgitation one year after surgery. J Thorac Cardiovasc Surg, 2001, 121 （1）：91-96.
  2. 2. 　Horii T, Tambara K, Nishimura K, et a1. Residual fibrosis affects a long-term result of left ventricular volume reduction surgery for dilated cardiomyopathy in a rat experimental study. Eur J Cardiothorac Surg, 2004, 26 （6）：1174-1179.
  3. 3. 　Zhang C, Hou J, Zheng S, et a1. Vascularized atrial tissue patch cardiomyoplasty with omentopexy improves cardiac performance after myocardial infarction. Ann Thorac Surg, 2011, 92 （4）：1435-1442.
  4. 4. 　Yuan Ye K, Sullivan KE, Black LD. Encapsulation of cardiomyocytes in a fibrin hydrogel for cardiac tissue engineering. J Vis Exp, 2011, （55）：3251.
  5. 5. 　Wang B, Borazjani A, Tahai M, et a1. Fabrication of cardiac patch with decellularized porcine myocardial scaffold and bone marrow mononuclear cells. J Biomed Mater Res A, 2010, 94 （4）：1100-1110.
  6. 6. 　Chiu LY, Radisic M. Scaffolds with covalently immobilized VEGF and Angiopoietin-1 for vascularization of engineered tissues. Biomaterials, 2010, 31 （2）：226-241.
  7. 7. 　Cui J, Li J, Mathison M, et a1. A clinically relevant large-animal model for evaluation of tissue-engineered cardiac surgical patch materials. Cardiovasc Revasc Med, 2005, 6 （3）：113-120.
  8. 8. 　Ratcliffe MB, Wallace AW, Salahieh A, et a1. Ventricular volume, chamber stiffness, and function after anteroapical aneurysm plication in the sheep. J Thorac Cardiovasc Surg, 2000, 119 （1）：115-124.
  9. 9. 　Pozzobon M, Bollini S, Iop L, et a1. Human bone marrow-derived CD133 （＋） cells delivered to a collagen patch on cryoinjured rat heart promote angiogenesis and arteriogenesis. Cell Transplant, 2010, 19 （10）：1247-1260.
  10. 10. 　Gaebel R, Ma N, Liu J, et a1. Patterning human stem cells and endothelial cells with laser printing for cardiac regeneration. Biomaterials, 2011, 32 （35）：9218-9230.
  11. 11. 　Yoshikawa E, Marui A, Tsukashita M, et a1. Carvedilol may alleviate late cardiac remodelling following surgical ventricular restoration. Eur J Cardiothorac Surg, 2010, 37 （2）：362-367.
  12. 12. 　Hsu CP, Huang CY, Wang JS, et a1. Extracellular matrix remodeling attenuated after experimental postinfarct left ventricular aneurysm repair. Ann Thorac Surg, 2008, 86 （4）：1243-1249.
  13. 13. 　Matsubayashi K, Fedak PW, Mickle DA, et a1. Improved left ventricular aneurysm repair with bioengineered vascular smooth muscle grafts. Circulation, 2003, 108 （Suppl 1）：II219-II225.
  14. 14. 　Di Donato M, Castelvecchio S, Menicanti L. Surgical treatment of ischemic heart failure：the Dor procedure. Circ J, 2009, 73 （Suppl A）：A1-A5.
  15. 15. 　Sakamoto Y, Mizuno A, Buckberg GD, et a1. Restoring the remodeled enlarged left ventricle：experimental benefits of in vivo porcine cardioreduction in the beating open heart. J Card Surg, 1998, 13 （6）：429-439.